Back to search results

Investigating 18F-DOPA PET/CT for Brain Tumor Management

This study is looking at whether a special type of scan, called an 18F-DOPA PET/CT, can help doctors make better decisions about treating brain tumors. You would receive a small amount of a radioactive drug, Fluorodopa F 18, through an IV, and then have a PET/CT scan. This scan combines a PET scan (which shows how tissues and organs are working) with a CT scan (which shows detailed images of bones and organs). The main goal is to see if adding this scan changes how doctors manage brain tumors in more than half of the patients. The study plans to enroll 47 adults aged 18 and older who have a brain tumor and need amino acid PET imaging.

Study design
This is an interventional study, meaning participants will receive a specific intervention (the 18F-DOPA PET/CT scan). It aims to enroll 47 participants.
What's involved
You would receive Fluorodopa F 18 intravenously and undergo a PET/CT scan over 30 minutes on one day. You would then be followed for 3 days after the scan.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for 3 days after the study intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06667726

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
Mayo Clinic
~47 participants
Updated 2026-04-28 on ClinicalTrials.gov
What's tested:Computed TomographyFluorodopa F 18Positron Emission Tomography

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Impact of 18F-DOPA PET/CT on clinical management
Measured over 3 days post-PET scan, up to 64 days

Conditions

Malignant Brain Neoplasm

Explore related trials

Brain Neoplasm

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Derek R. Johnson, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 and older
Diagnosis of a brain tumor
Indication for amino acid PET imaging, including presurgical evaluation, radiation planning, MR imaging indeterminate for progression versus treatment effect, or clinical need for enhanced monitoring
Ability to give appropriate consent or have an appropriate representative available to do so

Exclusion

Patient is unable to undergo PET imaging
Persons who are pregnant or nursing

What this trial measures

  • Impact of 18F-DOPA PET/CT on clinical management3 days post-PET scan, up to 64 days

    Will be measured using the Amino Acid PET Imaging Survey, to be completed by the provider after participant has received fluorodopa F 18 (18F-DOPA) positron emission tomography (PET)/computed tomography (CT). The survey consists of 4 questions, 1 multiple choice (what will PET scan be used for); 2 yes/no and one open-ended question related with how PET scan did or did not make a clinically meaningful impact in the management of patient care.